BioWorld

Jan. 30, 2004

Biogen Idec's Antegren Positive In Maintenance Trial For Crohn's

Despite a failed trial last year, Antegren now has garnered some positive Phase III data, meeting its primary endpoint by maintaining a response in Crohn's disease patients. (BioWorld Today) Read More

MedImmune Revenues Top $1B As Firm Sorts FluMist Options

Labopharm Reports Mixed Data For Tramadol, Plans NDA Filing

Chiron Earnings Rise Due To Vaccine, Other Product Growth

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 20, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...